Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China flag China · Delayed Price · Currency is CNY
2.030
0.00 (0.00%)
Sep 5, 2025, 3:00 PM CST

Kangmei Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
Operating Revenue
5,2545,1514,8274,1614,0545,267
Upgrade
Other Revenue
38.3538.3547.318.9598.79144.52
Upgrade
5,2925,1894,8744,1804,1535,412
Upgrade
Revenue Growth (YoY)
6.45%6.46%16.60%0.66%-23.27%-52.72%
Upgrade
Cost of Revenue
4,5144,5364,1453,7494,06129,046
Upgrade
Gross Profit
778.68653.37728.86431.1491.52-23,634
Upgrade
Selling, General & Admin
1,002959.781,0541,0371,2832,021
Upgrade
Research & Development
46.5851.4645.6225.459.2711.36
Upgrade
Other Operating Expenses
28.4430.76-311.78195.22653.49122.99
Upgrade
Operating Expenses
1,1091,067549.271,4713,1383,158
Upgrade
Operating Income
-330.39-413.53179.59-1,040-3,046-26,793
Upgrade
Interest Expense
-18.43-21.39-56.15-78.9-1,022-2,164
Upgrade
Interest & Investment Income
30.3776.4175.1840.77194.062.17
Upgrade
Currency Exchange Gain (Loss)
-----0.02-0.27
Upgrade
Other Non Operating Income (Expenses)
14.7922.74-34.04-16.04-1,041-137.84
Upgrade
EBT Excluding Unusual Items
-303.66-335.77164.57-1,095-4,915-29,093
Upgrade
Impairment of Goodwill
------44.29
Upgrade
Gain (Loss) on Sale of Investments
0.01-0-0.03---4.59
Upgrade
Gain (Loss) on Sale of Assets
11.3939.4719.610.9864.01-45.24
Upgrade
Asset Writedown
-31.8-31.47-99.69-307.46-2,634-1,424
Upgrade
Legal Settlements
-8.66-8.66-12.12-331.49-1,576-516.22
Upgrade
Other Unusual Items
371.07371.0738.03-931.5817,21793.85
Upgrade
Pretax Income
38.3634.65110.37-2,6648,155-31,033
Upgrade
Income Tax Expense
26.0822.576.829.75235.3962.55
Upgrade
Earnings From Continuing Operations
12.2812.08103.57-2,6947,920-31,096
Upgrade
Minority Interest in Earnings
-2.56-3.51-1.055.64-211.19
Upgrade
Net Income
9.718.57102.52-2,6887,918-31,085
Upgrade
Net Income to Common
9.718.57102.52-2,6887,918-31,085
Upgrade
Net Income Growth
-96.02%-91.64%----
Upgrade
Shares Outstanding (Basic)
14,86014,28910,25214,14813,89113,815
Upgrade
Shares Outstanding (Diluted)
14,86014,28910,25214,14813,89113,815
Upgrade
Shares Change (YoY)
33.39%39.38%-27.54%1.85%0.55%179.83%
Upgrade
EPS (Basic)
0.000.000.01-0.190.57-2.25
Upgrade
EPS (Diluted)
0.000.000.01-0.190.57-2.25
Upgrade
EPS Growth
-97.02%-94.00%----
Upgrade
Free Cash Flow
-251.57-489.34-417.27-798.0842.58729.67
Upgrade
Free Cash Flow Per Share
-0.02-0.03-0.04-0.060.000.05
Upgrade
Gross Margin
14.71%12.59%14.95%10.31%2.20%-
Upgrade
Operating Margin
-6.24%-7.97%3.69%-24.89%-73.37%-495.06%
Upgrade
Profit Margin
0.18%0.17%2.10%-64.31%190.68%-574.37%
Upgrade
Free Cash Flow Margin
-4.75%-9.43%-8.56%-19.09%1.03%13.48%
Upgrade
EBITDA
-52.87-131.8470.91-730.42-2,493-26,148
Upgrade
EBITDA Margin
-1.00%-2.54%9.66%-17.47%-60.04%-
Upgrade
D&A For EBITDA
277.52281.73291.32309.93553.19644.83
Upgrade
EBIT
-330.39-413.53179.59-1,040-3,046-26,793
Upgrade
EBIT Margin
-6.24%-7.97%3.68%-24.89%-73.37%-
Upgrade
Effective Tax Rate
67.99%65.13%6.16%-2.89%-
Upgrade
Revenue as Reported
5,2925,1894,8744,1804,1535,412
Upgrade
Advertising Expenses
-55.26193.19114.0699.5259.46
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.